As a first-in-class (Central Pattern Generator or CPG activator) approach, this tritherapy candidate called SPINALON has been identified and is currently under development for its capacity to temporarily induce episodes of involuntary locomotor movements. The primary objective of this Phase I/IIa study is to assess safety and tolerability of a single escalating dose of SPINALON (levodopa + carbidopa + buspirone) in chronic spinal cord-injured patients. As a secondary objective, preliminary evidence of efficacy will also be sought.

开始日期2013-07-01

申办/合作机构

Nordic Life Science Pipeline

[+1]

100 项与丁螺环酮/卡比多巴/左旋多巴相关的临床结果

登录后查看更多信息

100 项与丁螺环酮/卡比多巴/左旋多巴相关的转化医学

登录后查看更多信息

100 项与丁螺环酮/卡比多巴/左旋多巴相关的专利（医药）

登录后查看更多信息

项与丁螺环酮/卡比多巴/左旋多巴相关的文献（医药）

2024-12-01·Biomedicine & Pharmacotherapy

Acute effects of L-DOPA/carbidopa/buspirone (Spinalon™) on rhythmic electrical activity of the lumbosacral spinal cord in cats

Article

作者: Moreno-Castillo, Mayra ; Manjarrez, Elias ; Guertin, Pierre A

Discovered by Guertin and colleagues in 2004, Spinalon™ is a fixed-drug combination (L-DOPA, carbidopa, and buspirone) that can acutely induce temporary episodes of rhythmic locomotor-like activity in complete or near-complete spinal cord-injured (SCI) subjects. However, little is known about the mechanisms of action or the direct effects of Spinalon™ on neural elements of the central pattern generators (CPGs). Our study aims at characterizing the effects of Spinalon™ on electrical activity of the spinal cord in segmental areas known to contain key rhythmogenic elements of the CPGs (i.e., lumbosacral) for scratching and locomotion. We recorded spinal cord dorsum signals from decerebrate cats using a multielectrode array placed over the lumbosacral region. We found that a single intravenous injection of 100/25/7.5 mg/kg L-DOPA/carbidopa/buspirone (Spinalon™) specifically reduced the amplitude of electrical sinusoidal waves associated with fictive scratching and promoted the appearance of electrical sinusoidal-like waves occurring at frequencies compatible with fictive locomotion. These observations suggest a profound impact of Spinalon™ on the lumbosacral CPGs.

100 项与丁螺环酮/卡比多巴/左旋多巴相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多发性硬化症	临床2期	-	Nordic Life Science Pipeline	-
多发性硬化症	临床2期	-	Université Laval	-
多发性硬化症	临床2期	-	National Institutes of Health	-
脊髓损伤	临床2期	-	Nordic Life Science Pipeline	-
脊髓损伤	临床2期	-	National Institutes of Health	-
脊髓损伤	临床2期	-	Université Laval	-